

CITATION REPORT

List of articles citing

Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

DOI: 10.1080/09546634.2019.1698700

Journal of Dermatological Treatment, 2021, 32, 693-700.

Source: <https://exaly.com/paper-pdf/77004178/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. <i>Current Dermatology Reports</i> , 2021 , 10, 6-15	1.5	1
2	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021 , 8, 702776	4.9	4
1	IL-23 Class of Biologic Agents in Psoriatic Disease. <i>Updates in Clinical Dermatology</i> , 2022 , 41-51	0.2	